Are PCSK9 Inhibitors Cost Effective?

PharmacoEconomics - United Kingdom
doi 10.1007/s40273-018-0671-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

PCSK9 Peptide Inhibitors

Science-Business eXchange
2014English

Cost Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 (PCSK9) Inhibitors

Cardiovascular Disorders and Medicine
2019English

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors

INNOVATIONS in pharmacy
2017English

PCSK9 Inhibitors: When Statins Aren't Enough

Prescriber
Pharmacology
2017English

PCSK9 Inhibitors: A Technology Worth Paying For?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2015English

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice

Postgraduate Medicine
Medicine
2016English

How Cost-Effective Are New Cancer Drugs in the U.S.?

Expert Review of Pharmacoeconomics and Outcomes Research
MedicineHealth PolicyPharmacology
2020English

Metered Dose Inhalers Are Most Cost Effective for Asthma Drugs

BMJ
2001English

Are Expansions Cost Effective for Stock Exchanges? A Global Perspective

Journal of Banking and Finance
EconomicsEconometricsFinance
2001English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy